

Ultra-Low Dose Naltrexone - Research

Clinical Practice

Toljan K, Vrooman B. [Low-Dose Naltrexone \(LDN\)-Review of Therapeutic Utilization. Med Sci \(Basel\).](#) 2018 Sep 21;6(4):82. doi: 10.3390/medsci6040082. PMID: 30248938; PMCID: PMC6313374.

Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Friedmann N. [Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex.](#) J Pain. 2005 Jun;6(6):392-9. doi: 10.1016/j.jpain.2005.01.356. PMID: 15943961.

Webster LR, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N. [Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain.](#) J Pain. 2006 Dec;7(12):937-46. doi: 10.1016/j.jpain.2006.05.005. PMID: 17157780.

Hay JL, La Vincente SF, Somogyi AA, Chapleo CB, White JM. [Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects.](#) Eur J Pain. 2011 Mar;15(3):293-8. doi: 10.1016/j.ejpain.2010.07.009. Epub 2010 Aug 21. PMID: 20728384.

Cruciani RA, Lussier D, Miller-Saultz D, Arbuck DM. [Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone.](#) J Pain Symptom Manage. 2003 Jun;25(6):491-4. doi: 10.1016/s0885-3924(03)00139-8. PMID: 12782427.

Crain SM, Shen KF. [Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability.](#) Pain. 2000 Feb;84(2-3):121-31. doi: 10.1016/s0304-3959(99)00223-7. PMID: 10666516.

Largent-Milnes TM, Guo W, Wang HY, Burns LH, Vanderah TW. [Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.](#) J Pain. 2008 Aug;9(8):700-13. doi: 10.1016/j.jpain.2008.03.005. Epub 2008 May 12. PMID: 18468954; PMCID: PMC5469510.